Amundi Has $94.42 Million Stock Holdings in Humana Inc. $HUM

Amundi reduced its stake in Humana Inc. (NYSE:HUM) by 1.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 387,288 shares of the insurance provider’s stock after selling 7,355 shares during the quarter. Amundi’s holdings in Humana were worth $94,417,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Humana by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 14,199,096 shares of the insurance provider’s stock worth $3,471,395,000 after purchasing an additional 226,224 shares during the last quarter. Dodge & Cox increased its position in shares of Humana by 5.6% during the second quarter. Dodge & Cox now owns 11,352,920 shares of the insurance provider’s stock worth $2,775,562,000 after buying an additional 597,705 shares during the period. Pzena Investment Management LLC raised its stake in Humana by 6.5% during the second quarter. Pzena Investment Management LLC now owns 4,076,667 shares of the insurance provider’s stock worth $996,664,000 after buying an additional 247,744 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Humana by 1.9% in the second quarter. Geode Capital Management LLC now owns 3,130,829 shares of the insurance provider’s stock valued at $762,233,000 after buying an additional 57,267 shares during the period. Finally, Norges Bank acquired a new position in Humana in the second quarter valued at $397,079,000. 92.38% of the stock is currently owned by institutional investors.

Humana Trading Up 2.0%

Shares of Humana stock opened at $257.97 on Monday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.02 and a current ratio of 2.02. Humana Inc. has a 52 week low of $206.87 and a 52 week high of $315.35. The stock has a 50 day moving average price of $262.52 and a two-hundred day moving average price of $257.33. The stock has a market capitalization of $31.03 billion, a PE ratio of 24.18, a price-to-earnings-growth ratio of 1.51 and a beta of 0.46.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share for the quarter, topping analysts’ consensus estimates of $2.95 by $0.29. Humana had a return on equity of 12.86% and a net margin of 1.02%.The company had revenue of $32.65 billion for the quarter, compared to analyst estimates of $31.99 billion. During the same period in the prior year, the firm earned $4.16 earnings per share. Humana’s revenue for the quarter was up 11.1% on a year-over-year basis. As a group, equities analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, December 26th. Humana’s dividend payout ratio (DPR) is currently 33.18%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on HUM. Wells Fargo & Company increased their price target on Humana from $344.00 to $347.00 and gave the stock an “overweight” rating in a report on Tuesday, October 7th. Evercore ISI began coverage on Humana in a research note on Monday, September 22nd. They set an “in-line” rating and a $295.00 target price for the company. Sanford C. Bernstein lifted their target price on Humana from $269.00 to $341.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Jefferies Financial Group upgraded Humana from a “hold” rating to a “buy” rating and increased their price target for the stock from $253.00 to $313.00 in a report on Friday. Finally, Guggenheim reaffirmed a “buy” rating on shares of Humana in a research report on Friday, October 3rd. Nine research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $296.84.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.